Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

(2022) Ahmed Omar Kaseb et al.   Lancet Gastroenterology & Hepatology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

(2021) E. A. Rozeman et al.   NATURE MEDICINE

Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

(2021) Ming Lei et al.   CLINICAL CANCER RESEARCH

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

(2021) Dominik Pfister et al.   NATURE

VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

(2021) P. Schmid et al.   ANNALS OF ONCOLOGY

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

(2020) Myriam Chalabi et al.   NATURE MEDICINE

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma

(2020) David J. Pinato et al.   HEPATOLOGY

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

(2019) Jing Liu et al.   OncoImmunology

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease

(2019) Peter A. Szabo et al.   Nature Communications

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology

(2017) Sonja Gordic et al.   JOURNAL OF HEPATOLOGY

Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies

(2017) Wenjun Zhang et al.   LABORATORY INVESTIGATION

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice

(2017) Elena Burova et al.   MOLECULAR CANCER THERAPEUTICS

Recurrence of Hepatocellular Cancer After Resection

(2015) Parissa Tabrizian et al.   ANNALS OF SURGERY

Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?

(2015) Marc-Antoine Allard et al.   JOURNAL OF HEPATOLOGY

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

(2014) Matthew D Hellmann et al.   LANCET ONCOLOGY

Risk factors of post‐operative recurrence and adequate surgical approach to improve long‐term outcomes of hepatocellular carcinoma

(2012) Junichi Shindoh et al.   HPB

Effects of pre-operative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: Implication of circulating cancer cells by detection of α-fetoprotein mRNA

(2010) MASAHIRO MURAKAMI et al.   Experimental and Therapeutic Medicine